Search

Your search keyword '"Baker, Ross A."' showing total 1,408 results
Start Over Author "Baker, Ross A."
1,408 results on '"Baker, Ross A."'

1. Standardization of definition and management for bleeding disorder of unknown cause: communication from the SSC of the ISTH

Author

Baker, Ross I., Choi, Philip, Curry, Nicola, Gebhart, Johanna, Gomez, Keith, Henskens, Yvonne, Heubel-Moenen, Floor, James, Paula, Kadir, Rezan Abdul, Kouides, Peter, Lavin, Michelle, Lordkipanidze, Marie, Lowe, Gillian, Mumford, Andrew, Mutch, Nicola, Nagler, Michael, Othman, Maha, Pabinger, Ingrid, Sidonio, Robert, Thomas, Will, and O’Donnell, James S.

Published
2024
Full Text
View/download PDF

3. Type 1 VWD classification revisited: novel insights from combined analysis of the LoVIC and WiN studies

Author

Atiq, Ferdows, Blok, Robin, van Kwawegen, Calvin B., Doherty, Dearbhla, Lavin, Michelle, van der Bom, Johanna G., O'Connell, Niamh M., de Meris, Joke, Ryan, Kevin, Schols, Saskia E. M., Byrne, Mary, Heubel-Moenen, Floor C. J. I., van Galen, Karin P. M., Preston, Roger J. S., Cnossen, Marjon H., Fijnvandraat, Karin, Baker, Ross I., Meijer, Karina, James, Paula, Di Paola, Jorge, Eikenboom, Jeroen, Leebeek, Frank W. G., and O'Donnell, James S.

Published
2024
Full Text
View/download PDF

4. Correction: Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study

Author

Martin, Thomas, Dimopoulos, Meletios-Athanasios, Mikhael, Joseph, Yong, Kwee, Capra, Marcelo, Facon, Thierry, Hajek, Roman, Špička, Ivan, Baker, Ross, Kim, Kihyun, Martinez, Gracia, Min, Chang-Ki, Pour, Ludek, Leleu, Xavier, Oriol, Albert, Koh, Youngil, Suzuki, Kenshi, Casca, France, Macé, Sandrine, Risse, Marie-Laure, and Moreau, Philippe

Published
2023
Full Text
View/download PDF

5. Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study

Author

Martin, Thomas, Dimopoulos, Meletios-Athanasios, Mikhael, Joseph, Yong, Kwee, Capra, Marcelo, Facon, Thierry, Hajek, Roman, Špička, Ivan, Baker, Ross, Kim, Kihyun, Martinez, Gracia, Min, Chang-Ki, Pour, Ludek, Leleu, Xavier, Oriol, Albert, Koh, Youngil, Suzuki, Kenshi, Casca, France, Macé, Sandrine, Risse, Marie-Laure, and Moreau, Philippe

Published
2023
Full Text
View/download PDF

8. VWF–ADAMTS13 axis dysfunction in children with sickle cell disease treated with hydroxycarbamide vs blood transfusion

Author

Fogarty, Helen, Ahmad, Azaz, Atiq, Ferdows, Doherty, Dearbhla, Ward, Soracha, Karampini, Ellie, Rehill, Aisling, Leon, Gemma, Byrne, Ciara, Geoghegan, Rosena, Conroy, Helena, Byrne, Mary, Budde, Ulrich, Schneppenheim, Sonja, Sheehan, Ciara, Ngwenya, Noel, Baker, Ross I., Preston, Roger J. S., Tuohy, Emma, McMahon, Corrina, and O’Donnell, James S.

Published
2023
Full Text
View/download PDF

9. Direct oral anticoagulants or vitamin K antagonists in emergencies: comparison of management in an observational study

Author

Chen, V., Young, L., Merriman, E., Curnow, J., Gallus, A., Boey, J., Tan, Chee Wee, McRae, S., Hugman, A., Joseph, J., Harper, P., Brighton, T., Royle, G., Crowther, H., Tran, H., Campbell, P., Baker, R., Baker, Ross I., Gilmore, Grace, Chen, Vivien, Young, Laura, Merriman, Eileen, Curnow, Jennifer, Joseph, Joanne, Tiao, Jim Y., Chih, Jun, McRae, Simon, Harper, Paul, Tan, Chee W., Brighton, Timothy, Royle, Gordon, Hugman, Amanda, Hankey, Graeme J., Crowther, Helen, Boey, Jirping, Gallus, Alexander, Campbell, Philip, and Tran, Huyen

Published
2023
Full Text
View/download PDF

11. Sustained VWF-ADAMTS-13 axis imbalance and endotheliopathy in long COVID syndrome is related to immune dysfunction

Author

Fogarty, Helen, Ward, Soracha E., Townsend, Liam, Karampini, Ellie, Elliott, Stephanie, Conlon, Niall, Dunne, Jean, Kiersey, Rachel, Naughton, Aifric, Gardiner, Mary, Byrne, Mary, Bergin, Colm, O'Sullivan, Jamie M., Martin-Loeches, Ignacio, Nadarajan, Parthiban, Bannan, Ciaran, Mallon, Patrick W., Curley, Gerard F., Preston, Roger J.S., Rehill, Aisling M., Baker, Ross I., Cheallaigh, Cliona Ni, O'Donnell, James S., O’Connell, Niamh, Ryan, Kevin, Kenny, Dermot, and Fazavana, Judicael

Published
2022
Full Text
View/download PDF

13. Long-term effectiveness of aripiprazole once-monthly for schizophrenia is maintained in the QUALIFY extension study

Author

Naber, Dieter, Baker, Ross A, Eramo, Anna, Forray, Carlos, Hansen, Karina, Sapin, Christophe, Peters-Strickland, Timothy, Nylander, Anna-Greta, Hertel, Peter, Schmidt, Simon Nitschky, Loze, Jean-Yves, and Potkin, Steven G

Subjects
Pharmacology and Pharmaceutical Sciences, Biomedical and Clinical Sciences, Mental Health, Brain Disorders, Clinical Research, Schizophrenia, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Adolescent, Adult, Antipsychotic Agents, Aripiprazole, Dose-Response Relationship, Drug, Electrocardiography, Female, Humans, International Cooperation, Longitudinal Studies, Male, Middle Aged, Psychiatric Status Rating Scales, Retrospective Studies, Young Adult, Aripiprazole once-monthly, Maintenance treatment, Quality of life, Medical and Health Sciences, Psychology and Cognitive Sciences, Psychiatry, Clinical sciences
Abstract

ObjectiveTo evaluate long-term safety and effectiveness of continued treatment with aripiprazole once-monthly 400mg (AOM 400) in patients with schizophrenia.MethodsPatients who completed the QUALIFY study (NCT01795547) in the AOM 400 arm were eligible for 6 additional once-monthly injections of AOM 400 during an open-label, 24-week extension (NCT01959035). Safety data were collected at each visit. Effectiveness measures included change from baseline in health-related qualify of life and functioning on the Heinrichs-Carpenter Quality of Life scale (QLS) and Clinical Global Impression - Severity (CGI-S) scale.ResultsOf the 88 patients enrolled, 77 (88%) completed the extension study. Most common treatment-emergent adverse events (incidence ≥2%) were weight increased (6/88, 7%), toothache (3/88, 3%) and headache (3/88, 3%). Effectiveness was maintained during the extension study, with small but continued improvements from baseline: the least squares mean (LSM) change (95% CI) from baseline to week 24 was 2.32 (-1.21 to 5.85) for the QLS total score and -0.10 (-0.26 to 0.06) for the CGI-S score. The aggregated LSM change (95% CI) from baseline of the lead-in study to week 24 of the extension study was 11.54 (7.45 to 15.64) for the QLS total score and -0.98 (-1.18 to -0.79) for the CGI-S score.ConclusionsAOM 400 was well tolerated in patients continuing AOM treatment during the extension phase of the QUALIFY study. Robust and clinically meaningful improvements in health-related quality of life and functioning were maintained, further supporting the long-term clinical benefits of AOM 400 for the treatment of patients with schizophrenia.

Published
2018

15. Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial

Author

Matasar, Matthew J, Capra, Marcelo, Özcan, Muhit, Lv, Fangfang, Li, Wei, Yañez, Eduardo, Sapunarova, Katya, Lin, Tongyu, Jin, Jie, Jurczak, Wojciech, Hamed, Aryan, Wang, Ming-Chung, Baker, Ross, Bondarenko, Igor, Zhang, Qingyuan, Feng, Jifeng, Geissler, Klaus, Lazaroiu, Mihaela, Saydam, Guray, Szomor, Árpád, Bouabdallah, Krimo, Galiulin, Rinat, Uchida, Toshiki, Soler, Lidia Mongay, Cao, Anjun, Hiemeyer, Florian, Mehra, Aruna, Childs, Barrett H, Shi, Yuankai, and Zinzani, Pier Luigi

Published
2021
Full Text
View/download PDF

17. Reduced sexual dysfunction with aripiprazole once-monthly versus paliperidone palmitate: results from QUALIFY.

Author

Potkin, Steven, Loze, Jean-Yves, Forray, Carlos, Baker, Ross, Sapin, Christophe, Peters-Strickland, Timothy, Beillat, Maud, Nylander, Anna-Greta, Hertel, Peter, Steen Andersen, Henrik, Eramo, Anna, Hansen, Karina, and Naber, Dieter

Subjects
Adolescent, Adult, Antipsychotic Agents, Aripiprazole, Female, Humans, Male, Middle Aged, Paliperidone Palmitate, Prolactin, Quality of Life, Schizophrenia, Sexual Dysfunction, Physiological, Young Adult
Abstract

Sexual dysfunction, a common side effect of antipsychotic medications, may be partly caused by dopamine antagonism and elevation of prolactin. In QUALIFY, a randomized study, aripiprazole once-monthly 400 mg (AOM 400), a dopamine D2 receptor partial agonist, showed noninferiority and subsequent superiority versus paliperidone palmitate (PP), a dopamine D2 receptor antagonist, on the Heinrichs-Carpenter Quality-of-Life Scale (QLS) in patients with schizophrenia aged 18-60 years. Sexual dysfunction (Arizona Sexual Experience Scale) and serum prolactin levels were also assessed. Odds for sexual dysfunction were lower with AOM 400 versus PP [week 28 adjusted odds ratio (95% confidence interval), 0.29 (0.14-0.61); P=0.0012] in men [0.33 (0.13-0.86); P=0.023], women [0.14 (0.03-0.62); P=0.0099], and patients aged 18-35 years [0.04 (

Published
2017

18. Relationship between response to aripiprazole once-monthly and paliperidone palmitate on work readiness and functioning in schizophrenia: A post-hoc analysis of the QUALIFY study.

Author

Potkin, Steven, Loze, Jean-Yves, Forray, Carlos, Baker, Ross, Sapin, Christophe, Peters-Strickland, Timothy, Beillat, Maud, Nylander, Anna-Greta, Hertel, Peter, Nitschky Schmidt, Simon, Ettrup, Anders, Eramo, Anna, Hansen, Karina, and Naber, Dieter

Subjects
Adult, Antipsychotic Agents, Aripiprazole, Drug Administration Schedule, Drug Therapy, Combination, Employment, Female, Humans, Male, Middle Aged, Paliperidone Palmitate, Schizophrenia
Abstract

Schizophrenia is a chronic disease with negative impact on patients employment status and quality of life. This post-hoc analysis uses data from the QUALIFY study to elucidate the relationship between work readiness and health-related quality of life and functioning. QUALIFY was a 28-week, randomized study (NCT01795547) comparing the treatment effectiveness of aripiprazole once-monthly 400 mg and paliperidone palmitate once-monthly using the Heinrichs-Carpenter Quality-of-Life Scale as the primary endpoint. Also, patients capacity to work and work readiness (Yes/No) was assessed with the Work Readiness Questionnaire. We categorized patients, irrespective of treatment, by work readiness at baseline and week 28: No to Yes (n = 41), Yes to Yes (n = 49), or No at week 28 (n = 118). Quality-of-Life Scale total, domains, and item scores were assessed with a mixed model of repeated measures. Patients who shifted from No to Yes in work readiness showed robust improvements on Quality-of-Life Scale total scores, significantly greater than patients not ready to work at week 28 (least squares mean difference: 11.6±2.6, p

Published
2017

19. Multidimensional Assessment of Functional Outcomes in Schizophrenia: Results From QUALIFY, a Head-to-Head Trial of Aripiprazole Once-Monthly and Paliperidone Palmitate

Author

Potkin, Steven G, Loze, Jean-Yves, Forray, Carlos, Baker, Ross A, Sapin, Christophe, Peters-Strickland, Timothy, Beillat, Maud, Nylander, Anna-Greta, Hertel, Peter, Schmidt, Simon Nitschky, Eramo, Anna, Hansen, Karina, and Naber, Dieter

Subjects
Biological Psychology, Pharmacology and Pharmaceutical Sciences, Biomedical and Clinical Sciences, Psychology, Brain Disorders, Mental Health, Clinical Trials and Supportive Activities, Clinical Research, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Good Health and Well Being, Adult, Antipsychotic Agents, Aripiprazole, Employment, Female, Humans, Male, Paliperidone Palmitate, Patient Satisfaction, Psychiatric Status Rating Scales, Quality of Life, Schizophrenia, Severity of Illness Index, Single-Blind Method, Surveys and Questionnaires, Treatment Outcome, aripiprazole once-monthly, paliperidone palmitate, quality of life, functioning, schizophrenia, Medical and Health Sciences, Psychology and Cognitive Sciences, Psychiatry, Biomedical and clinical sciences, Health sciences
Abstract

BackgroundQUALIFY was a 28-week, randomized, open-label, head-to-head trial that assessed improvements across multiple measures in stable patients with schizophrenia with aripiprazole once-monthly 400 mg vs paliperidone palmitate.MethodsSecondary effectiveness assessments included physician-rated readiness for work using the Work Readiness Questionnaire, the Clinical Global Impression-Severity and Clinical Global Impression-Improvement scales, and quality of life with the rater-blinded Heinrichs-Carpenter Quality of Life Scale. Patients assessed their treatment satisfaction and quality of life with Subjective Well-Being under Neuroleptic Treatment-short version and Tolerability and Quality of Life questionnaires.ResultsOdds of being ready for work at week 28 were significantly higher with aripiprazole once-monthly 400 mg vs paliperidone palmitate (adjusted odds ratio, 2.67; 95% CI, 1.39-5.14; P=.003). Aripiprazole once-monthly 400 mg produced numerically or significantly greater improvements from baseline vs paliperidone palmitate in all Quality of Life Scale items. With aripiprazole once-monthly 400 mg vs paliperidone palmitate at week 28, there were significantly more Clinical Global Impression-Severity and Clinical Global Impression-Improvement responders (adjusted odds ratio, 2.26; P=.010, and 2.51; P=.0032) and significantly better Clinical Global Impression-Improvement scores (least squares mean treatment difference, -0.326; 95% CI, -0.60 to -0.05; P=.020). Numerically larger improvements with aripiprazole once-monthly 400 mg vs paliperidone palmitate were observed for patient-rated scales Subjective Well-Being under Neuroleptic Treatment-short version and Tolerability and Quality of Life. Partial correlations were strongest among clinician-rated and among patient-rated scales but poorest between clinician and patient-rated scales.ConclusionsConsistently greater improvements were observed with aripiprazole once-monthly 400 mg vs paliperidone palmitate across all measures. Partial correlations between scales demonstrate the multidimensionality of various measures of improvement. More patients on aripiprazole once-monthly 400 mg were deemed ready to work by the study end.Trial registryNational Institutes of Health registry, NCT01795547, https://clinicaltrials.gov/ct2/results?id=NCT01795547).

Published
2017

24. Type 1 VWD classification revisited - novel insights from combined analysis of the LoVIC and WiN studies

Author

Atiq, Ferdows, primary, Blok, Robin, additional, van Kwawegen, Calvin, additional, Doherty, Dearbhla, additional, Lavin, Michelle, additional, van der Bom, Johanna G, additional, O'Connell, Niamh M, additional, de Meris, Joke, additional, Ryan, Kevin, additional, Schols, Saskia E.M., additional, Byrne, Mary B, additional, Heubel-Moenen, Floor C.J.I., additional, van Galen, Karin P.M., additional, Preston, Roger J.S., additional, Cnossen, Marjon H., additional, Fijnvandraat, Karin, additional, Baker, Ross Ian, additional, Meijer, Karina, additional, James, Paula D., additional, Di Paola, Jorge, additional, Eikenboom, Jeroen C.J., additional, Leebeek, Frank W.G., additional, and O'Donnell, James S., additional

Published
2023
Full Text
View/download PDF

27. Erratum to ‘Illustrated State-of-the-Art Capsules of the ISTH 2024 Congress’ [Research and Practice in Thrombosis and Haemostasis Volume 8, Issue 4, May 2024, 102432]

Author

Ward, Chris, Curry, Nicola, El-Ekiaby, Magdy, Jurk, Kerstin, Versteeg, Henri H., Keragala, Charithani, Burstyn-Cohen, Tal, Antoniak, Silvio, Suzuki, Yuko, Baker, Ross I., Christophe, Olivier, Revel-Vilk, Shoshana, Hart, Alice, Deppermann, Carsten, Tran, Huyen, Pozzi, Nicola, Kahr, Walter H.A., Grover, Steven P., Wenzel, Philip, Brown, Ashley C., Oury, Cécile, Shea, Susan M., Fredenburgh, James, Passam, Freda H., Winearls, James, Moore, Hunter B., Tole, Soumitra, Merriman, Eileen, Barnes, Geoffrey D., Leonardo Liu, Z., Sholzberg, Michelle, Rivera, José, and Marín-Quilez, Ana

Published
2024
Full Text
View/download PDF

29. 'Safety is about partnership': Safety through the lens of patients and caregivers.

Author

Kuluski, Kerry, Asselbergs, Maaike, Baker, Ross, Burns, Katharina Kovacs, Bruno, Frances, Saragosa, Marianne, MacLaurin, Anne, Flintoft, Virginia, and Jeffs, Lianne

Subjects
MEDICAL quality control, CAREGIVER attitudes, DISCLOSURE, HEALTH facilities, FOCUS groups, PATIENT participation, CAREGIVERS, RESEARCH methodology, INTERVIEWING, PATIENTS' attitudes, QUALITATIVE research, RESPONSIBILITY, SELF-efficacy, QUALITY assurance, SOUND recordings, ACCESS to information, COMMUNICATION, RESEARCH funding, JUDGMENT sampling, STATISTICAL sampling, THEMATIC analysis, PATIENT education, PATIENT safety, HEALTH self-care
Abstract

Introduction: Creating safer care is a high priority across healthcare systems. Despite this, most systems tend to focus on mitigating past harm, not creating proactive solutions. Managers and staff identify safety threats often with little input from patients and their caregivers during their health encounters. Methods: This is a qualitative descriptive study utilizing focus groups and one‐to‐one interviews with patients and caregivers who were currently using (or had previously used) services in health systems across Canada. Data were analysed via inductive thematic analysis to understand existing and desired strategies to promote safer and better quality care from the perspectives of patients and caregivers. Findings: In our analysis, we identified three key themes (safety strategies) from patients' and caregivers' perspectives and experiences: Using Tools and Approaches for Engaging Patients and Caregivers in their Care; Having Accountability Processes and Mechanisms for Safe Care; and Enabling Patients and Caregivers Access to Information. Conclusions: Safety is more than the absence of harm. Our findings outline a number of suggestions from patients and caregivers on how to make care safer, ranging from being valued on teams, participating as members of quality improvement tables, having access to health information, having access to an advocate to help make sense of information and having processes in place for disclosure and closure. Future work can further refine, implement and evaluate these strategies in practice. Patient or Public Contributions: An advisory group guided the research and was co‐chaired by a patient partner. Members of the advisory group spanned patient and caregiver organizations and health sectors across Canada and included three patient partners and leaders who work closely with patients and caregivers in their day‐to‐day work. In the research itself, we engaged 28 patients and caregivers from across Canada to learn about their safety experiences and learn what safer care looks like from their perspectives. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

30. OA-48 Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed multiple myeloma (IKEMA): final overall survival analysis

Author

Yong, Kwee, primary, Martin, Thomas, additional, Dimopoulos, Meletios, additional, Mikhael, Joseph, additional, Capra, Marcelo, additional, Facon, Thierry, additional, Hájek, Roman, additional, Špička, Ivan, additional, Baker, Ross, additional, Kim, Kihyun, additional, Martinez, Gracia, additional, Min, Chang-Ki, additional, Pour, Ludek, additional, Leleu, Xavier, additional, Oriol, Albert, additional, Koh, Youngil, additional, Suzuki, Kenshi, additional, Casca, France, additional, Macé, Sandrine, additional, Risse, Marie-Laure, additional, and Moreau, Philippe, additional

Published
2023
Full Text
View/download PDF

31. Isatuximab plus carfilzomib and dexamethasone in patients with early versus late relapsed multiple myeloma: IKEMA subgroup analysis

Author

Facon, Thierry, primary, Moreau, Philippe, additional, Baker, Ross, additional, Min, Chang-Ki, additional, Leleu, Xavier, additional, Mohty, Mohamad, additional, Karlin, Lionel, additional, Armstrong, Nicole M., additional, Tekle, Christina, additional, Schwab, Sandrine, additional, Risse, Marie-Laure, additional, and Martin, Thomas, additional

Published
2023
Full Text
View/download PDF

32. Illustrated State-of-the-Art Capsules of the ISTH 2024 Congress

Author

Ward, Chris, Curry, Nicola, El-Ekiaby, Magdy, Jurk, Kerstin, Versteeg, Henri H., Keragala, Charithani, Burstyn-Cohen, Tal, Antoniak, Silvio, Suzuki, Yuko, Baker, Ross I., Christophe, Olivier, Revel-Vilk, Shoshana, Hart, Alice, Deppermann, Carsten, Tran, Huyen, Pozzi, Nicola, Kahr, Walter H.A., Grover, Steven P., Wenzel, Philip, Brown, Ashley C., Oury, Cécile, Shea, Susan M., Fredenburgh, James, Passam, Freda H., Winearls, James, Moore, Hunter B., Tole, Soumitra, Merriman, Eileen, Barnes, Geoffrey D., Liu, Z. Leonardo, and Sholzberg, Michelle

Published
2024
Full Text
View/download PDF

38. Endothelial cell activation, Weibel-Palade body secretion, and enhanced angiogenesis in severe COVID-19

Author

Karampini, Ellie, primary, Fogarty, Helen, additional, Elliott, Stephanie, additional, Morrin, Hannah, additional, Bergin, Colm, additional, O’Sullivan, Jamie M., additional, Byrne, Mary, additional, Martin-Loeches, Ignacio, additional, Mallon, Patrick W., additional, Curley, Gerard F., additional, Glavey, Siobhan, additional, Baker, Ross I., additional, Lavin, M., additional, Preston, Roger J.S., additional, Cheallaigh, Cliona Ni, additional, Ward, Soracha E., additional, and O’Donnell, James S., additional

Published
2023
Full Text
View/download PDF

39. Validating lactate dehydrogenase (LDH) as a component of the PLASMIC predictive tool (PLASMIC-LDH)

Author

Liam, Christopher Chin Keong, primary, Tiao, Jim Yu-Hsiang, additional, Yap, Yee Yee, additional, Lee, Yi Lin, additional, Sathar, Jameela, additional, McRae, Simon, additional, Davis, Amanda, additional, Curnow, Jennifer, additional, Bird, Robert, additional, Choi, Philip, additional, Angchaisuksiri, Pantep, additional, Tien, Sim Leng, additional, Lam, Joyce Ching Mei, additional, Oh, Doyeun, additional, Kim, Jin Seok, additional, Yoon, Sung-Soo, additional, Wong, Raymond Siu-Ming, additional, Lauren, Carolyn, additional, Merriman, Eileen Grace, additional, Enjeti, Anoop, additional, Smith, Mark, additional, and Baker, Ross Ian, additional

Published
2023
Full Text
View/download PDF

40. Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia A

Author

Mahlangu, Johnny, Kuliczkowski, Kazimierz, Karim, Faraizah Abdul, Stasyshyn, Oleksandra, Kosinova, Marina V., Lepatan, Lynda Mae, Skotnicki, Aleksander, Boggio, Lisa N., Klamroth, Robert, Oldenburg, Johannes, Hellmann, Andrzej, Santagostino, Elena, Baker, Ross I., Fischer, Kathelijn, Gill, Joan C., P'Ng, Stephanie, Chowdary, Pratima, Escobar, Miguel A., Khayat, Claudia Djambas, Rusen, Luminita, Bensen-Kennedy, Debra, Blackman, Nicole, Limsakun, Tharin, Veldman, Alex, St. Ledger, Katie, and Pabinger, Ingrid

Published
2016
Full Text
View/download PDF

42. Antipsychotic treatment patterns in Alzheimer’s disease patients with agitation: a cohort study using the UK clinical practice research datalink

Author

Tran, Cam Thanh, B��g, Martin, Collings, Shuk-Li, Johnson, Michelle, Qizilbash, Nawab, Lind, Stefan, Baker, Ross A., and J��rgensen, Kristian Tore

Subjects
Aged, 80 and over, Cohort Studies, Alzheimer Disease, Humans, General Medicine, Psychomotor Agitation, United Kingdom, Aged, Antipsychotic Agents, Retrospective Studies
Abstract

There is a lack of robust epidemiological evidence on antipsychotic (AP) use in patients with agitation in Alzheimer���s disease (AD). Authors studied AP use in patients with AD and agitation and compared their use with patients with other or no neuropsychiatric symptoms (NPS). A retrospective cohort study in the UK Clinical Practice Research Datalink, included patients with AD between January 1st, 2015, and December 31st, 2017. AP use was compared between patients with agitation, other types of NPS and no NPS. There were 24,464 patients with AD, median follow-up of 1.1 years (interquartile range [IQR] 0.5���2.1), and median age 83 years (78���88). A larger percentage of patients with agitation (n = 2432) were prescribed APs (38.2%) than other NPS (n = 13,076, 20.4%) and no NPS (n = 11,816, 12.2%). Compared to patients with no NPS, adjusted hazard ratios for AP use were 3.45 (95% CI 2.86���4.17) for patients with agitation and 1.31 (95% CI 1.19���1.44) for patients with other NPS. Among users of APs, the treatment discontinuation rate at six months was 44.8% in patients with agitation (other NPS 57.1%; no NPS 63.5%). Patients with AD and agitation were frequently prescribed APs and for long periods in routine clinical practice in the UK. The high real-life usage of APs suggests that physicians prefer using APs for the treatment of agitation despite recommendations against their long-term use. These data support a need for AP therapies that better address known safety concerns with currently used APs to treat agitation in elderly patients with AD.

Published
2022

44. If Republican Party doesn't regain Senate, blame Trump

Author

Baker, Ross K.

Subjects
United States. Senate -- Evaluation, Ex-presidents -- Influence -- Endorsements -- Political activity, Congressional candidates -- Political activity -- Endorsements, News, opinion and commentary, Republican Party (United States) -- Evaluation
Abstract

Byline: Ross K. Baker, Board of Contributors, USA TODAY Republican Senate leader Mitch McConnell, in a speech before a Chamber of Commerce luncheon in Kentucky last month, observed that in [...]

Published
2022

50. Phase 1/2a Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of Pxs-5505 in Patients with Primary, Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis

Author

Baker, Ross, primary, Baskar, Jana, additional, Charlton, Brett, additional, Hobbs, Gabriela S., additional, Jarolimek, Wolfgang, additional, Lee, Sung-Eun, additional, Masarova, Lucia, additional, and Watson, Anne-Marie, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results